Assessing compound activity to accelerate drug discovery

In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.

Compounds in drug

Scientists are continually searching for improved ways to identify new drugs. While the traditional method of high‑throughput screening is still frequently used, better screening techniques are being created. Now, a new screening strategy has been developed to evaluate drug compounds by their activity, rather than just their structure. According to the scientists behind the technique, called biological activity-based modelling (BABM), the method could speed up the search for novel therapies against diseases, including COVID-19.

    To read this article in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Merck, X-Chem, Horizon Discovery, Beckman Coulter

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.